Compare PESI & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PESI | PYXS |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.8M | 243.5M |
| IPO Year | 1992 | 2021 |
| Metric | PESI | PYXS |
|---|---|---|
| Price | $13.36 | $4.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 184.4K | ★ 763.9K |
| Earning Date | 11-10-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $60,661,000.00 | $2,820,000.00 |
| Revenue This Year | $8.35 | N/A |
| Revenue Next Year | $82.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.25 | $0.83 |
| 52 Week High | $16.50 | $5.55 |
| Indicator | PESI | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 57.03 | 53.01 |
| Support Level | $12.02 | $3.67 |
| Resistance Level | $12.75 | $5.55 |
| Average True Range (ATR) | 0.66 | 0.46 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 81.44 | 44.68 |
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: The treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.